摘要
目的:探讨齐拉西酮与利培酮两种药物在精神分裂症患者治疗中的临床效果。方法:将64例精神分裂症患者分为齐拉西酮组和利培酮组,每组各32例。分别给予两组患者齐拉西酮或利培酮治疗,观察两组患者的疗效和安全性。结果:在治疗4周后,两组患者的两项量表评估有明显差异(P<0.05);齐拉西酮组患者不良反应率为9.38%低于利培酮组的18.75%,差异有统计学意义(P<0.05)。结论:齐拉西酮治疗精神分裂症患者的临床效果优于利培酮治疗。
Objective： To investigate clinical effects of Ziprasidone and Risperidone in treatment of schizophrenia. Methods：64 schizophrenic patients were divided into Ziprasidone group（ treated with Ziprasidone） and Risperidone group（ treated with Risperidone）. The efficacies of safety of the two groups were observed. Results： In 4 weeks after treatment,there were significant differences in the two scales between the two group（ P〈0. 05）. The adverse reaction rates of Ziprasidone group and Risperidone group were9. 38% and 18. 75%. Conclusions： In the treatment of schizophrenia,Ziprasidone has good clinical effects and higher safety than Risperidone.
出处
《中国民康医学》
2015年第13期15-16,共2页
Medical Journal of Chinese People’s Health
